COMMUNIQUÉS West-GlobeNewswire

Better Choice Company Inc. Announces Closing of $17.2 Million Private Placement, a 16.2% Increase From the Amount Previously Announced
06/05/2019
BROOKLYN, N.Y., May 06, 2019 (GLOBE NEWSWIRE) -- Better Choice Company Inc. (OTCQB: BTTR) (the “Company”) today announced that it has closed its previously announced private placement for aggregate gross proceeds of [...]
Amedisys Celebrates More Than 7,000 Nurses During National Nurses Week
06/05/2019
BATON ROUGE, La., May 06, 2019 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ:AMED), one of the nation’s leading home healthcare, hospice and personal care companies, celebrates National Nurses Week by honoring more than 7, [...]
Otonomy Reports First Quarter 2019 Financial Results and Provides Corporate Update
06/05/2019
OTO-313 Phase 1/2 trial in tinnitus initiated; results expected in first half of 2020 OTIPRIO ® co-promotion agreement completed with Glenmark Therapeutics OTIVIDEX™ Phase 3 trial in Ménière’s disease on track for [...]
Alpha Pro Tech, Ltd. Announces Revenue of $12.3 Million, $0.09 in EPS, for the First Quarter of 2019
06/05/2019
Revenue in the first quarter of 2019 was $12.3 million, an increase of 7.5% compared to $11.4 million in the first quarter of 2018. Income from operations increased to 8.1% of net sales in the first quarter of 2019, up [...]
LeMaitre Vascular to Present at Upcoming Investor Conferences
06/05/2019
BURLINGTON, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will be participating in two investor conferences in May. David Roberts, President, is scheduled to [...]
Teligent, Inc. Announces First Quarter 2019 Results
06/05/2019
BUENA, N.J., May 06, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2019 [...]
Progenics Pharmaceuticals Issues Statement Regarding Velan Capital
06/05/2019
Progenics Board Deeply Committed to Enhancing Value for all Shareholders Repeated Efforts to Engage Meaningfully with Velan Rebuffed No Shareholder Action Required at this Time NEW YORK, May 06, 2019 (GLOBE NEWSWIRE [...]
TransMedics Announces Closing of its Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
06/05/2019
ANDOVER, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart [...]
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2019 and Highlights Recent Corporate Progress
06/05/2019
SAN DIEGO, May 06, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes [...]
The Ensign Group Reports First Quarter Results
06/05/2019
Conference Call and Webcast scheduled for tomorrow, May 7, 2019 at 10:00 am PT MISSION VIEJO, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of [...]
Codexis Reports First Quarter 2019 Financial Results
06/05/2019
Total revenues increase 11% to $15.6 million, product revenue up 30% Recent highlights include Third CodeEvolver ® Platform Technology Agreement and Multi-Year Enzyme Supply and Licensing Agreement with Tate & Lyle [...]
Forty Seven Inc. to Report First Quarter 2019 Financial Results on Monday, May 13, 2019
06/05/2019
MENLO PARK, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today [...]
Rubius Therapeutics to Announce First Quarter 2019 Financial Results
06/05/2019
CAMBRIDGE, Mass., May 06, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new [...]
BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations
06/05/2019
BELBUCA ® Net Sales Increased by 134% versus Prior Year to All-time High of $18.7 Million Symproic ® Acquisition and Commercial Integration Successfully Completed Company Raises Full-Year BELBUCA Net Sales Expectations [...]
ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights
06/05/2019
-- Succession of topline data readouts expected, starting with Pivotal ADVOCATE Phase III trial of C5a receptor inhibitor avacopan in ANCA Vasculitis in Q4 2019 -- -- Conference call today at 5:00 p.m. Eastern Time -- [...]
Profound Medical Announces First Quarter 2019 Financial Results
06/05/2019
- Receives Notification of FDA Acceptance of 510(k) Application Filing for TULSA-PRO® - TORONTO, May 06, 2019 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; OTCQX:PRFMF) (“Profound” or the “Company”), the only [...]
GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex
06/05/2019
- Achieved primary efficacy measure with both EPIDIOLEX doses as compared to placebo - - Represents the fifth consecutive positive Phase 3 pivotal trial for EPIDIOLEX - - Expect to file sNDA in Q4 2019 - CARLSBAD, Calif [...]
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019
06/05/2019
- Epidiolex U.S. Q1 net sales of $33.5m - - Positive Phase 3 pivotal results in Tuberous Sclerosis Complex, sNDA submission expected in Q4 2019 - - Conference call today at 4:30 p.m. EDT - CARLSBAD, Calif., May 06, 2019 [...]
Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update
06/05/2019
Strong Crysvita® (burosumab) Launch Continues with Approximately 730 Patients on Reimbursed Commercial Therapy in the United States NOVATO, Calif., May 06, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ [...]

Pages